Niacin modulates pro-inflammatory cytokine secretion. A potential mechanism involved in its anti-atherosclerotic effect

Open Cardiovascular Medicine Journal

Volumn 7, Issue 1, 2013, Pages 90-98

  Lipszyc, Pedro Saul ^a   Cremaschi, Graciela Alicia ^b   Zubilete, María Zorrilla ^a   Bertolino, Maria Laura Aón ^c   Capani, Francisco ^c   Genaro, Ana Maria ^a,b   Walda, Miriam Ruth ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Centre de Estudios Farmacologicos y Botanicos   (Argentina)

^c Instituto de Investigaciones Cardiológicas ININCA CONICET UBA   (Argentina)

Author keywords

Atherosclerosis; Inflammation; Macrophages; Niacin; Nicotinic acid receptor; Pro inflammatory cytokines

Indexed keywords

CD68 ANTIGEN; CHOLESTEROL; DRUG RECEPTOR; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; NICOTINIC ACID; NICOTINIC ACID RECEPTOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIATHEROSCLEROTIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; BINDING SITE; C57BL 6 MOUSE; CELL STIMULATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WEIGHT GAIN;

EID: 84885349276     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401307010090     Document Type: Article

References (31)

1. Lusis AJ. Atherosclerosis. Nature 2000; 407(6801): 233-41.
2. Robbie L, Libby P. Inflammation and atherothrombosis. Ann N Y Acad Sci 2001; 947: 167-80.
3. Cheng JW. Recognition, pathophysiology, and management of acute myocardial infarction. Am J Health Syst Pharm 2001; 58(18): 1709-18.
4. Pepine CJ. Why vascular biology matters. Am J Cardiol 2001; 88(8A): 5K-9K.
5. Brown BG, Zhao XQ. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 2008; 101(8A): 58-62.
6. Canner PL, Furberg CD, McGovern ME. Benefits of Niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2006; 97(4): 477-9.
7. Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003; 9(3): 352-5.
8. Wise A, Foord SM, Fraser NJ, et al. Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid. J Biol Chem 2003; 278(11): 9869-74.
9. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341(7): 498-511.
10. Petrovic D. The role of vascular endothelial growth factor gene as the genetic marker of atherothrombotic disorders and in the gene therapy of coronary artery disease. Cardiovasc Hematol Agents Med Chem. 2010, 8(1), 47-54.
11. Pleskovič A, Vraspir-Porenta O, Zorc-Pleskovič R, Petrovič D, Zorc M, Milutinović A. Deficiency of mast cells in coronary artery endarterectomy of male patients with type 2 diabetes. Cardiovasc Diabetol 2011; 14(10): 40.
12. Petrovic D, Verhovec R, Globocnik PM, Osredkar J, Peterlin B. Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes. Cardiology 2007; 107(4): 291-5.
13. Candore G, Vasto S, Colonna-Romano G, et al. Cytokine Gene Polymorphisms in Multifactorial Conditions. Koen, V. Ed; Florida; CRC Press: 2006; pp. 363-78.
14. Licastro F, Candore G, Lio D, et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing 2005; 18: 2-8.
15. Stephens JW, Humphries SE. The molecular genetics of cardiovascular disease: clinical implications. J Intern Med 2003; 253(2): 120-7.
16. Schaub A, Futterer A, Pfeffer K. PUMA-G, an IFN-gammainducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily. Eur J Immunol 2001; 31(12): 3714-25.
17. Digby JE, McNeill E, Dyar OJ, Lam V, Greaves DR, Choudhury RP. Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis 2010; 209(1): 89-95.
18. Westphal S, Borucki K, Taneva E, Makarova R, Luley C. Extended-release Niacin raises adiponectin and leptin. Atherosclerosis 2007; 193(2): 361-5.
19. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009; 202(1): 68-75.
20. Kwon WY, Suh GJ, Kim KS, Kwak YH. Niacin attenuates lung inflammation and improves survival during sepsis by downregulating the nuclear factor-κB pathway. Crit Care Med 2011; 39(2): 328-34.
21. Wu BJ, Chen K, Barter PJ, Rye KA. Niacin Inhibits Vascular Inflammation via the Induction of Heme Oxygenase-1. Circulation 2012, 125(1), 150-8
22. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 1985; 57(1): 65-73.
23. Nishina PM, Lowe S, Verstuyft J. Naggert, J.K. Kuypers, F.A. Paigen B. Effects of dietary fats from animal and plant sources on diet-induced fatty streak lesions in C57BL/6J mice. J Lipid Res 1993; 34(8): 1413-22.
24. Shockley KR, Witmer D, Burgess-Herbert SL, Paigen B, Churchill GA. Effects of atherogenic diet on hepatic gene expression across mouse strains. Physiol Genomics 2009; 39(3): 172-82.
25. Zhang X, Goncalves R, Mosser DM. The isolation and characterization of murine macrophages. Curr Protoc Immunol 2008; 14(83): 14-8.
26. Lorenzen A, Stannek C, Lang H, Andrianov V, Kalvinsh I, Schwabe U. Characterization of a G Protein-Coupled Receptor for Nicotinic Acid. Mol Pharmacol 2001; 59(2): 349-57.
27. Plum J, Huang C, Grabensee B, Schrör K, Meyer-Kirchrath, J. Prostacyclin enhances the expression of LPS/INF-gamma-induced nitric oxide synthase in human monocytes. Nephron 2002; 91(13): 391-8.
28. Yeh CH, Chou W, Chu CC, et al. Anticancer agent 2-methoxyestradiol improves survival in septic mice by reducing the production of cytokines and nitric oxide. Shock 2011; 36(5): 510-6.
29. van der Wal AC. Smooth muscle cells in coronary atherosclerotic plaques: phenotypic variations and clinical consequences. Eur J Clin Invest 2001; 31(11): 923-5.
30. Lukasova M, Malaval C, Gille A, Kero J, Offermanns S. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest 2011; 121(3): 1163-73.
31. Digby JE, Martinez F, Jefferson A, et al. Anti-Inflammatory Effects of Nicotinic Acid in Human Monocytes Are Mediated by GPR109a Dependent Mechanisms. Arterioscler Thromb Vasc Biol 2012; 32(3): 669-76.